Barclays on Edwards Lifesciences (EW): Good News, Bad News on TAVR Consensus

Barclays maintains an 'Equalweight' on Edwards Lifesciences (NYSE: EW) price target of $80.00.

Analyst, Matthew Taylor said, "While not all of the information is new, in general, we view the consensus statement as good-news, bad-news for EW. The good news is that societies are being very proactive to lay groundwork for suggested use and rollout of TAVR (indicative of the excitement around the therapy, despite PARTNER A not being approved in the US yet). The bad news is that some of the statements around use in high risk patients and the pace of the rollout are more cautious than EW's guidance and expectations, in our view."

For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.

Shares of Edwards Lifesciences closed at $71.09 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Investec Double Upgrades Alkem Laboratories Ltd (ALKEM:IN) to Buy
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'